• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kronos Advanced Technologies Inc. (KNOS) Is ‘One to Watch’

By: Investor Brand Network
February 08, 2022 at 13:58 PM EST
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.
  • Kronos’ planned West Virginia factory improvements are on schedule, expected to finish in Q1 2022
  • The company is currently developing new consumer electronics products in the wellness category
  • Kronos has filed an S-1 with the SEC regarding a proposed secondary stock offering
  • The company is preparing to manufacture its patented air purifiers in its U.S. factory to satisfy increasing demand
  • Kronos will increase production of its 5-ply graphene mask, the only one of its kind made in the United States

Kronos Advanced Technologies (OTC: KNOS) develops and sells a variety of disruptive, advanced, state-of-the-art air filtration and purification systems that fully remove harmful allergens, bacteria, viruses (including the flu), and even gasses from indoor breathing spaces, including healthcare and other settings.

Kronos’ own patented medical-grade technology is tested as the most effective clean air solution on the market. Kronos filters particles down to .0146 micron (.0146μm) – far beyond the 3 microns (0.3μm) of…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to KNOS are available in the company’s newsroom at https://ibn.fm/KNOS

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article

More News

View More
News headline image
Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference ↗
Today 2:02 EDT
Via MarketBeat
Tickers VXRT
News headline image
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near ↗
Today 1:02 EDT
Via MarketBeat
Tickers MS SRPT
News headline image
Biogen Eyes Wave of Phase III Readouts as It Expands Beyond Neuroscience ↗
Today 0:02 EDT
Via MarketBeat
Tickers BIIB MS
News headline image
Viking Therapeutics Advances VK2735 Obesity Drug Into Phase 3 After 15% Weight Loss ↗
September 14, 2026
Via MarketBeat
Tickers MS VKTX
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
September 14, 2026
Via MarketBeat
Topics Intellectual Property
Tickers MS REGN

Recent Quotes

View More
Symbol Price Change (%)
AMZN  253.54
-3.24 (-1.26%)
AAPL  333.08
+0.81 (0.24%)
AMD  493.41
-22.72 (-4.40%)
BAC  59.47
-3.22 (-5.14%)
GOOG  345.71
+10.26 (3.06%)
META  665.60
+17.57 (2.71%)
MSFT  505.41
+9.78 (1.97%)
NVDA  210.96
-7.33 (-3.36%)
ORCL  144.79
-5.49 (-3.65%)
TSLA  358.97
-6.47 (-1.77%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap